Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 03, 2022 at 07:09 am EDT
Share
Deciphera Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 35.97 million compared to USD 23.22 million a year ago. Net loss was USD 43.04 million compared to USD 79.84 million a year ago. Basic loss per share from continuing operations was USD 0.55 compared to USD 1.37 a year ago.
For the nine months, revenue was USD 97.69 million compared to USD 71.95 million a year ago. Net loss was USD 133 million compared to USD 211.57 million a year ago. Basic loss per share from continuing operations was USD 1.82 compared to USD 3.65 a year ago.
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.
DECIPHERA PHARMACEUTICALS, INC. 
